X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2440) 2440
Publication (297) 297
Book Chapter (38) 38
Book Review (30) 30
Magazine Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hepatitis c virus (1332) 1332
index medicus (1316) 1316
hepatitis c (1189) 1189
direct-acting antivirals (1044) 1044
humans (987) 987
gastroenterology & hepatology (723) 723
antiviral agents - therapeutic use (699) 699
antiviral agents (597) 597
ribavirin (596) 596
hepatitis c, chronic - drug therapy (571) 571
hepatitis (557) 557
interferon (521) 521
sofosbuvir (481) 481
hcv (432) 432
male (403) 403
health aspects (401) 401
sustained virological response (400) 400
infectious diseases (381) 381
female (380) 380
hepacivirus - genetics (373) 373
middle aged (362) 362
genotype (357) 357
hepacivirus - drug effects (345) 345
cirrhosis (343) 343
therapy (334) 334
virus-infection (329) 329
infection (320) 320
drug therapy, combination (316) 316
direct-acting antiviral (310) 310
treatment outcome (308) 308
direct-acting antiviral agents (301) 301
virus diseases (297) 297
direct acting antivirals (288) 288
hepatitis c - drug therapy (277) 277
liver (275) 275
virology (257) 257
infections (254) 254
analysis (251) 251
adult (250) 250
patients (250) 250
care and treatment (245) 245
drug therapy (242) 242
liver cirrhosis (242) 242
biological response modifiers (238) 238
aged (234) 234
genotype 1 infection (228) 228
viruses (228) 228
sustained virologic response (219) 219
chronic hepatitis c (217) 217
hepatitis c, chronic - virology (211) 211
pharmacology & pharmacy (211) 211
hiv (192) 192
digestive system diseases (189) 189
hepatocellular carcinoma (189) 189
antiviral agents - adverse effects (185) 185
daclatasvir (185) 185
ribavirin - therapeutic use (185) 185
pegylated interferon (182) 182
antiviral agents - administration & dosage (176) 176
treatment-naive patients (176) 176
genotype 1 (173) 173
hcv infection (172) 172
ledipasvir (171) 171
protease inhibitors (168) 168
telaprevir (166) 166
hepatology (164) 164
immunology (163) 163
hepatitis-c virus (160) 160
hepatitis c, chronic - complications (159) 159
antiviral agents - pharmacology (157) 157
medical research (157) 157
prevalence (156) 156
genotypes (155) 155
efficacy (150) 150
plus ribavirin (150) 150
medicine & public health (149) 149
gastroenterology and hepatology (147) 147
liver transplantation (147) 147
genetic aspects (146) 146
medicine, experimental (145) 145
safety (142) 142
direct‐acting antivirals (140) 140
microbiology (138) 138
fibrosis (137) 137
hepatocellular-carcinoma (135) 135
genotype & phenotype (134) 134
risk factors (133) 133
chronic hepatitis-c (125) 125
epidemiology (125) 125
transplantation (124) 124
antiviral therapy (122) 122
boceprevir (120) 120
medicine, general & internal (120) 120
review (119) 119
liver diseases (117) 117
simeprevir (117) 117
mortality (115) 115
treatment-naive (115) 115
hepatitis c - virology (112) 112
recurrence (112) 112
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2295) 2295
Korean (62) 62
Spanish (37) 37
Hungarian (24) 24
Japanese (17) 17
French (16) 16
German (16) 16
Russian (8) 8
Chinese (2) 2
Italian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 6, pp. 1578 - 1587
Journal Article
Liver International, ISSN 1478-3223, 07/2017, Volume 37, Issue 7, pp. 974 - 981
Background & Aims The aim of this study was to assess the efficacy and safety of direct‐acting antivirals (DAA)‐based antiviral therapies for HCV patients with... 
direct‐acting antiviral | stage 4‐5 chronic kidney disease | hepatitis C virus infection | meta‐analysis | meta-analysis | direct-acting antiviral | stage 4-5 chronic kidney disease | ASUNAPREVIR | RENAL-DISEASE | COMBINATION | DIALYSIS PATIENTS | PEGYLATED INTERFERON | GENOTYPE 1 INFECTION | HEMODIALYSIS | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | Renal Insufficiency, Chronic - complications | Time Factors | Adult | Female | Hepatitis C - complications | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Odds Ratio | Kidney - physiopathology | Hepacivirus - drug effects | Severity of Illness Index | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Renal Insufficiency, Chronic - physiopathology | Hepatitis C - diagnosis | Antiviral Agents - adverse effects | Hepatitis C - virology | Hepacivirus - growth & development | Aged | Sustained Virologic Response | Antiviral agents | Care and treatment | Chronic kidney failure | Hepatitis C virus | Health aspects | Analysis | Renal function | Ritonavir | Viruses | Disease control | Patients | Incidence | Confidence intervals | Hepatitis | Renal failure | Dialysis | Libraries | Kidney diseases | Safety | Hepatitis C | Kidney transplantation
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article